2010•Future OncologyRequires access

Sunitinib for Metastatic Renal Cell Carcinoma

Deborah Mukherji, James Larkin, Lisa M. Pickering

Abstract

Sunitinib is an orally available, multitargeted tyrosine kinase inhibitor licensed for the treatment of metastatic renal cell carcinoma. This article is an in-depth review of the mechanism of action of sunitinib, rationale for dose and schedule, toxicity and clinical efficacy. Other targeted therapies and treatment combinations for renal cell carcinoma are discussed. The use of sunitinib for other indications, biomarkers of response and future directions are explored.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 11 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Sunitinib, Medicine, Renal cell carcinoma, Tyrosine-kinase inhibitor, Toxicity, Oncology, Internal medicine, Pharmacology